Eli Lil­ly's an­ti­body cuts risk of Covid-19 by up to 80% among the most vul­ner­a­ble — but will it have a place next to vac­cines?

Eli Lil­ly says bam­lanivimab low­ered the risk of con­tract­ing symp­to­matic Covid-19 in a first-of-its-kind tri­al in­volv­ing nurs­ing home res­i­dents and staff, paving the way for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER